Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is May 22, 2025, covering a share repurchase executed on May 21, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing non-discretionary buyback agreement initiated on February 24, 2025.
Key Financial Metrics
- Shares Purchased (May 21, 2025): 567,590 ordinary shares.
- Price Range: Lowest price paid was 1,417.50 GBp; highest price paid was 1,434.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,427.19 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares Held: 213,947,923 ordinary shares following this transaction.
- Shares in Issue (Excluding Treasury): 4,101,310,936 ordinary shares.
- Total Voting Rights: 4,101,310,936.
- Cumulative Buyback (Since Feb 24, 2025): 44,877,620 ordinary shares.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing details a reduction in the number of shares in issue and an increase in treasury shares held by the company. Since the commencement of the current buyback program on February 24, 2025, the company has repurchased approximately 44.9 million shares. The specific transaction on May 21, 2025, added approximately 0.57 million shares to the treasury holding.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on February 24, 2025.
- Confirm the impact of the increased treasury share count (213,947,923) on earnings per share (EPS) calculations.
- Review the "Risk Factors" section of the 2024 Form 20-F for context on the forward-looking statement disclaimer.
- Check subsequent filings for updates on the cumulative buyback volume and remaining program duration.